Acceder

Publicaciones - Neurociencia Clínica y Experimental

Cargando...
Villaverde-González R. Updated Perspectives on the Challenges of Managing Multiple Sclerosis During Pregnancy. Degener Neurol Neuromuscul Dis. 2022 Jan 5;12:1-21. doi: 10.2147/DNND.S203406. eCollection 2022. Review. PubMed PMID: 35023987; PubMed Central PMCID: PMC8743861.
AÑO: 2022
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Häring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. PubMed PMID: 34605319; PubMed Central PMCID: PMC9024029.
AÑO: 2022; IF: 5.855
Costa T, Fernandez-Villalba E, Izura V, Lucas-Ochoa AM, Menezes-Filho NJ, Santana RC, de Oliveira MD, Araújo FM, Estrada C, Silva V, Costa SL, Herrero MT. Combined 1-Deoxynojirimycin and Ibuprofen Treatment Decreases Microglial Activation, Phagocytosis and Dopaminergic Degeneration in MPTP-Treated Mice. J Neuroimmune Pharmacol. 2021 Jun;16(2):390-402. doi: 10.1007/s11481-020-09925-8. Epub 2020 Jun 21. PubMed PMID: 32564332.
AÑO: 2021; IF: 7.285
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallström E, Zhang X, Mareš M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. PubMed PMID: 34418400; PubMed Central PMCID: PMC8434816.
AÑO: 2021; IF: 59.935
Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, Berenguer-Ruiz L, Candeliere Merlicco A, Martinez-Navarro ML, Gracia Gil J, Romero-Sanchez CM, Alfaro-Saez A, Diaz I, Gimenez-Martinez J, Mendez-Miralles MA, Millan-Pascual J, Jimenez-Pancho J, Mola S, Sempere AP. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol. 2021 Feb;8(2):385-394. doi: 10.1002/acn3.51282. Epub 2020 Dec 25. PubMed PMID: 33369288; PubMed Central PMCID: PMC7886031.
AÑO: 2021; IF: 5.43
Siguiente >

Instituto de Investigación Sanitaria Acreditado

ISCII